Aerobic Exercise in Postexercise Cardiovascular Responses in Resistant Hypertension: a Cross-over Trial
Overview
Aerobic exercise has the potential to diminish blood pressure values. The aim of this study is to determine whether this potential is also applicable for those with resistant hypertension and whether exercise intensity plays a role in this context. We hypothesize that performing an aerobic exercise session reduces blood pressure values in resistant hypertensive patients in a dose-response relation with exercise intensity.
Full Title of Study: “Aerobic Exercise in Postexercise Cardiovascular Responses in Resistant Hypertension: a Cross-over Randomized Controlled Trial”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Treatment
- Masking: Single (Outcomes Assessor)
- Study Primary Completion Date: May 2015
Detailed Description
Exercise prescription is gathering great importance in preventive health. Several organizations endorse the performance of at least 150min/wk of moderate intensity or 75min/wk of higher intensities in order to achieve better health parameters in different contexts. Aerobic exercise is known to be an effective way to diminish BP levels post-session. These responses are widely applicable in hypertensive subjects, acting in aid of BP management treatment. Although these benefits of aerobic exercise are well known, few studies explore the potential of this intervention in resistant-to-treatment patients. Moreover, the effects different intensities of aerobic exercise in this population is scarce. Thus, the aim of this study is to determine the magnitude of BP responses, if there is any, of resistant hypertensive subjects to two different intensities of aerobic exercise, compared with a control session. For that, subjects will be enrolled for one pre-intervention cardiopulmonary exercise testing and three randomized intervention sessions: control, 50%HRmax and 75%HRmax. Prior and immediately after all intervention sessions (during 1h), forearm blood flow and reactive hyperemia will be assessed by venous occlusion plethysmography. After the sessions, 24h blood pressure will be assessed with an ambulatory blood pressure monitoring system.
Interventions
- Other: aerobic exercise
- aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
Arms, Groups and Cohorts
- No Intervention: Control
- sited rest for 45 minutes
- Experimental: higher intensity aerobic exercise
- 45 minutes of aerobic exercise at 75%HRmax
- Experimental: lower intensity aerobic exercise
- 45 minutes of aerobic exercise at 50%HRmax
Clinical Trial Outcome Measures
Primary Measures
- Ambulatory Blood Pressure Monitoring
- Time Frame: 22h
Secondary Measures
- Forearm blood flow
- Time Frame: 1h
- Accessed by venous occlusion plethysmography. Compared with pre-intervention values
- Reactive hyperemia
- Time Frame: pre and 30min post
- Accessed by venous occlusion plethysmography.
Participating in This Clinical Trial
Inclusion Criteria
resistant-to-treatment hypertensive subjects (24h ambulatory BP above 130/80, or daytime ambulatory BP above 135/85, or night-time ambulatory BP above 120/70 in spite use of 3 anti-hypertensive medications of different classes, being one diuretic; or use of 4 or more anti-hypertensive medications). Exclusion Criteria:
Muscle or skeletal abnormalities that preclude effort, abnormal exercise stress test, major illnesses that would preclude exercise effort or could influence in the outcome variables (pulmonary disease, valve disease, renal insufficiency, etc.)
Gender Eligibility: All
Minimum Age: 25 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Daniel Umpierre, PhD, Principal Investigator, Federal University of Health Science of Porto Alegre
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.